Clinical Research Network on Antimicrobial Resistance

The National Institute of Allergy and Infectious Diseases (NIAID), under the U.S. Department of Health and Human Services, has issued a forecast for a cooperative agreement opportunity titled "Clinical Research Network on Antimicrobial Resistance." This initiative continues NIAID’s commitment to combating the escalating global health threat posed by antimicrobial resistance (AMR), which severely limits effective treatment options for bacterial and fungal infections. AMR is of critical concern especially to vulnerable populations such as individuals with chronic conditions like cancer and diabetes. These patients face heightened risks of infection complications, leading to increased morbidity, mortality, and healthcare expenditures. Through this opportunity, NIAID aims to establish or support a Clinical Research Network that will address high-priority clinical research questions related to AMR. The scope of work includes conducting clinical trials and observational studies on bacterial and fungal infections with resistance concerns. Funded activities will include testing new antibiotics and alternative therapies, such as bacteriophage treatments, optimizing current antibiotic regimens, and evaluating the clinical utility of novel diagnostics, including their role in informing treatment strategies. This comprehensive effort is expected to both generate critical data and improve patient outcomes while informing future treatment guidelines. A key component of the program is workforce development, as NIAID seeks to cultivate the next generation of AMR-focused clinical researchers. The network will also serve as a platform for mentorship and training initiatives embedded in ongoing research operations. This effort aligns with NIAID’s mission to conduct and support research to understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. The program is forecasted to open for applications on July 1, 2026, with an application deadline of September 29, 2026. One award is expected to be made, with an estimated total program funding of $15 million. The project is anticipated to start on July 1, 2027, with the award announcement aligned with that date. No matching or cost-sharing is required for this opportunity. The funding instrument is a cooperative agreement, indicating substantial involvement by NIAID in program oversight and coordination. Eligible applicants include a wide range of entities: public and private institutions of higher education, nonprofits with or without IRS 501(c)(3) status (excluding IHEs), for-profit organizations (including small businesses), tribal organizations, city and township governments, special district governments, and faith-based or community-based organizations. There are no geographic restrictions mentioned, suggesting a nationwide scope. All inquiries should be directed to the Division of Microbiology and Infectious Diseases at [email protected]. The official notice does not include a direct PDF link, and as this is a forecasted opportunity, applicants should monitor Grants.gov and NIAID’s website for updates once the opportunity is formally posted.